Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care

Clinical Infectious Diseases

Volumn 43, Issue SUPPL. 4, 2006, Pages

  Schackman, Bruce R ^a   Merrill, Joseph O ^b   McCarty, Dennis ^c   Levi, Jeffrey ^d   Lubinski, Christine ^e  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d GEORGE WASHINGTON UNIVERSITY   (United States)

^e HIV Medicine Association   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BUPRENORPHINE; METHADONE;

CONFIDENTIALITY; COST EFFECTIVENESS ANALYSIS; ELECTRONIC MEDICAL RECORD; FINANCIAL MANAGEMENT; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTEGRATED HEALTH CARE SYSTEM; INVESTMENT; LEADERSHIP; LICENSING; MEDICAID; MEDICARE; OPIATE ADDICTION; OUTCOMES RESEARCH; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW;

EID: 33845418372     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Turner BJ, Laine C, Lin YT, Lynch K. Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence. Arch Intern Med 2005; 165:1769-76.
2. Jaffe JH. The swinging pendulum: the treatment of drug users in America. In: Dupont RI, Goldstein A, O'Donnell J, Brown B, eds. Handbook on drug abuse. Washington, DC: US Government Printing Office, 1979:3-16.
3. King R. The narcotics bureau and the Harrison Act: jailing the healers and the sick. Yale Law Journal 1953; 62:735-49.
4. Musto DF. The American disease: origins of narcotic control. New Haven, CT: Yale University Press, 1973.
5. Substance Abuse and Mental Health Services Administration. Buprenorphine. Available at: http://buprenorphine.samhsa.gov/index.html. Accessed 17 October 2006.
6. Join Together. National poll of physicians on barriers to widespread buprenorphine use. Join together, 2003. Available at: http://www.jointogether. org/resources/report-national-poll-of.html. Accessed 31 October 2006.
7. Merrill JO, Jackson TR, Schulman BA, et al. Methadone medical maintenance in primary care: an implementation evaluation. J Gen Intern Med 2005; 20:344-9.
8. McCarty D, Rieckmann T, Green C, Gallon S, Knudsen J. Training rural practitioners to use buprenorphine; using The Change Book to facilitate technology transfer. J Subst Abuse Treat 2004; 26:203-8.
9. Legal Action Center. Confidentiality: a guide to the federal laws and regulations. New York, NY: Legal Action Center, 1991.
10. Bozzette SA, Berry SH, Duan N, et al. The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. N Engl J Med 1998; 339:1897-904.
11. McCarty D, Frank RG, Denmead GC. Methadone maintenance and state Medicaid managed care programs. Milbank Q 1999; 77:341-62, 274.
12. Henry J. Kaiser Family Foundation. Medicare and HIV/AIDS. Palo Alto, CA: Henry J. Kaiser Family Foundation, 2004.
13. United States Pharmacopiea. Comprehensive listing of drugs in the USP model guidelines for drugs approved through October 2004. Rockville, MD: United States Pharmacopiea, 2005.
14. Kates J, Penner M, Crutsinger-Perry B, Leggoe A, Singleton N. National ADAP Monitoring Project: annual report. Washington, DC: Henry J. Kaiser Family Foundation and National Alliance of State and Territorial AIDS Directors, 2005.
15. National Association of State Alcohol and Drug Abuse Directors. States' perspectives on buprenorphine and office based medication assisted opioid dependency treatment. Washington, DC: National Association of State Alcohol and Drug Abuse Directors, 2004.
16. Health Resources and Services Administration. Special Projects of National Significance 2005 report to CARE Act grantees: buprenorphine initiative. Rockville, MD: Health Resources and Services Administration, 2005.
17. French MT, Drummond M. A research agenda for economic evaluation of substance abuse services. J Subst Abuse Treat 2005; 29:125-37.
18. Rosenheck R, Kosten T. Buprenorphine for opiate addiction: potential economic impact. Drug Alcohol Depend 2001; 63:253-62.
19. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost effectiveness in health and medicine. New York: Oxford University Press, 1996.
20. Schackman BR, Freedberg KA, Goldie SJ, Weinstein MC, Swartz K. Budget impact of Medicaid Section 1115 demonstrations for early HIV treatment in Georgia and Massachusetts. Health Care Financ Rev 2005; 26:67-80.
21. Barnett PG, Zaric GS, Brandeau ML. The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. Addiction 2001; 96:1267-78.
22. Ubel PA, Hirth RA, Cbernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2003; 163:1637-41.
23. Doran CM, Shanahan M, Mattick RP, Ali R, White J, Bell J. Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. Drug Alcohol Depend 2003; 71:295-302.
24. Mattick RP, Ali R, White JM, O'Brien S, Wolk S, Danz C. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction 2003; 98:441-52.
25. Harris AH, Gospodarevskaya E, Ritter AJ. A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting. Pharmacoeconomics 2005; 23:77-91.
26. Gibson AE, Doran CM, Bell JR, Ryan A, Lintzeris N. A comparison of buprenorphine treatment in clinic and primary care settings: a randomised trial. Med J Aust 2003; 179:38-42.
27. Sindelar JL, Jofre-Bonet M, French MT, McLellan AT. Cost-effectiveness analysis of addiction treatment: paradoxes of multiple outcomes. Drug Alcohol Depend 2004; 73:41-50.